

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT	DISEASE Brain anaplastic astrocytoma	PHYSICIAN	ORDERING PHYSICIAN Yeh, Yi-Chen	SPECIMEN	SPECIMEN SITE Brain
	NAME Hsu, I Feng		MEDICAL FACILITY Taipei Veterans General Hospital		SPECIMEN ID S112-03016 A (PF23044)
	DATE OF BIRTH 30 September 1983		ADDITIONAL RECIPIENT None		SPECIMEN TYPE Slide Deck
	SEX Male		MEDICAL FACILITY ID 205872		DATE OF COLLECTION 31 January 2023
	MEDICAL RECORD # 40089701		PATHOLOGIST Not Provided		SPECIMEN RECEIVED 01 May 2023

Biomarker Findings

Microsatellite status - MS-Stable
Tumor Mutational Burden - 0 Muts/Mb

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

IDH1R132H
ATRX splice site 4557+1G>T
FUBP1 rearrangement intron 18
TP53 R282W

Report Highlights

- Variants with **diagnostic implications** that may indicate a specific cancer type: **ATRX** splice site 4557+1G>T (p. 4), **IDH1** R132H (p. 3)
- Targeted therapies with **NCCN categories of evidence** in this tumor type: **Ivosidenib** (p. 6)
- Variants that may inform **nontargeted treatment approaches** (e.g., chemotherapy) in this tumor type: **IDH1** R132H (p. 3)
- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 7)
- Variants with **prognostic implications** for this tumor type that may impact treatment decisions: **IDH1** R132H (p. 3)

BIOMARKER FINDINGS

Microsatellite status - MS-Stable

Tumor Mutational Burden - 0 Muts/Mb

GENOMIC FINDINGS

IDH1 - R132H

10 Trials see p. 7

THERAPY AND CLINICAL TRIAL IMPLICATIONS

No therapies or clinical trials. See Biomarker Findings section

No therapies or clinical trials. See Biomarker Findings section

THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)

none

THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)

Ivosidenib

2A

Olutasidenib

☐ NCCN category

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

ATRX - splice site 4557+1G>T p. 4 **TP53** - R282W p. 5
FUBP1 - rearrangement intron 18 p. 4

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

ORDERED TEST # ORD-1620418-01

BIOMARKER FINDINGS

BIOMARKER

Microsatellite status

RESULT

MS-Stable

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors¹⁻³, including approved therapies nivolumab and pembrolizumab⁴. In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and

experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, $p=0.001$)⁵.

FREQUENCY & PROGNOSIS

MSI-High has been reported in 3-8% of adult or pediatric astrocytomas and was generally not associated with Lynch syndrome⁶⁻⁸. Low-level MSI has been reported in 5-9% of glioblastoma (GBM) samples⁹⁻¹¹. A large-scale study did not find high-level microsatellite instability (MSI-H) in any of 129 GBM samples⁹, although a small-scale study reported MSI-H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs¹². The frequency of MSI has been reported to be increased in relapsed compared to primary GBM⁹, in GBMs with a previous lower grade astrocytoma¹⁰, and in giant cell GBM compared to classic GBM¹¹.

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor¹³. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2¹³⁻¹⁵. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers¹⁶⁻¹⁸. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins^{13,15,17-18}.

BIOMARKER

Tumor Mutational Burden

RESULT

0 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1¹⁹⁻²¹, anti-PD-1 therapies¹⁹⁻²², and combination nivolumab and ipilimumab²³⁻²⁸. In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported^{19,29-30}. However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE mutations

have benefited from treatment with anti-PD-1³¹⁻³² or anti-PD-L1³³ therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD-1 or PD-L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.

FREQUENCY & PROGNOSIS

Anaplastic astrocytoma harbors a median TMB of 1.8 mutations per megabase (mut/Mb), and 2% of cases have high TMB (>20 muts/Mb)³⁴. For pediatric patients, high TMB has been reported in a subset of high-grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB³⁵⁻³⁶. Increased TMB has been reported to correlate with higher tumor grade in glioma³⁷ and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency

(bMMRD)³¹, as well as with shorter OS of patients with diffuse glioma³⁸.

FINDING SUMMARY

Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma³⁹⁻⁴⁰ and cigarette smoke in lung cancer⁴¹⁻⁴², treatment with temozolomide-based chemotherapy in glioma⁴³⁻⁴⁴, mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes⁴⁵⁻⁴⁹, and microsatellite instability (MSI)^{45,48-49}. This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents^{19,29-33}.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 08 May 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1620418-01

GENOMIC FINDINGS

GENE

IDH1

ALTERATION

R132H

HGVS VARIANT

NM_005896.2: c.395G>A (p.R132H)

VARIANT CHROMOSOMAL POSITION

chr2:209113112

VARIANT ALLELE FREQUENCY (% VAF)

38.9%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

IDH1 mutations that lead to production of 2-HG, most commonly R132 alterations, may predict sensitivity to IDH1-mutation-specific inhibitors such as ivosidenib⁵⁰ and olutasidenib⁵¹. A Phase 1B/2 basket study of the IDH1 inhibitor olutasidenib reported a DCR of 48% (12/25, 2 PR) in patients with glioma; patients with other solid tumors including intrahepatic cholangiocarcinoma and chondrosarcoma achieved SD⁵¹. A Phase 1 study of the pan-IDH1/IDH2 inhibitor vorasidenib for patients with IDH1- or IDH2-mutated glioma reported an ORR of 18% (4/22; RANO criteria) and median PFS of 31.4 months for non-enhancing cases and median PFS of 7.5 months for the overall glioma population (n=52)⁵². Preclinical studies suggested that IDH1 neomorphic mutations may also confer sensitivity to PARP inhibitors⁵³⁻⁵⁶. In a Phase 1 trial of the PD-L1 inhibitor atezolizumab for patients with glioblastoma (GBM), 2/3 patients with IDH1-mutated tumors experienced clinical benefit (1 PR, 1 long-term SD, 1 short-term SD), whereas none of the 8 patients with IDH1-wildtype GBM experienced benefit (8/8 PD); significantly

longer PFS and a trend toward longer OS were observed for patients with IDH1-mutated tumors compared with the patients with IDH1-wildtype tumors³³. A Phase 1 trial of the oral brain-penetrant mutated IDH1 selective inhibitor DS-1001 for patients with recurrent or progressive IDH1-mutated glioma reported 2 CRs and 4 PRs for 35 patients with enhancing tumors and 1 PR and 3 minor responses (MRs) for 12 patients with non-enhancing tumors⁵⁷. Preclinical data indicate that IDH1-mutated glioma may be sensitive to the glutaminase inhibitor telaglenastat in combination with radiotherapy⁵⁸.

— Nontargeted Approaches —

IDH1/2 mutations are associated with improved survival outcomes for patients with glioma treated with radiation or alkylating chemotherapy (NCCN CNS Cancers Guidelines, v2.2022). Addition of procarbazine, lomustine, and vincristine (PCV) to radiotherapy significantly improved OS for patients with IDH-mutated (9.4 vs. 5.7 years, HR=0.59) but not IDH-non-mutated (1.3 versus 1.8 years, HR=1.14) anaplastic oligodendroglioma/oligoastrocytoma⁵⁹. As adjuvant therapy after radiation for patients with IDH1/2-mutated anaplastic astrocytoma, temozolomide⁶⁰ or PCV⁶¹ improved median PFS and median OS relative to radiotherapy or temozolomide alone, respectively.

FREQUENCY & PROGNOSIS

IDH1 mutation is characteristic of low-grade gliomas and secondary glioblastoma, and is relatively rare in primary glioblastoma⁶²⁻⁶⁶. In the TCGA datasets, IDH1 mutation has been found in 77% of lower grade glioma cases and in 5% of glioblastoma cases⁶⁷⁻⁶⁸. IDH1 mutations are highly prevalent in grade 2 and grade 3 astrocytoma, oligodendroglioma, and oligoastrocytoma, reported

in 43-100% of grade 2 tumors and 45-93% of grade 3 tumors⁶⁹⁻⁷². IDH1/2 mutations are a strong favorable prognostic marker for OS in Grade 2-3 glioma, particularly in combination with 1p/19q codeletion (NCCN CNS Cancers Guidelines, v2.2022). Several studies have found IDH1 mutations to be associated with improved prognosis and longer PFS and OS in patients with various types of glioma including anaplastic astrocytoma and GBM^{66,73-79}.

FINDING SUMMARY

The isocitrate dehydrogenases IDH1 and IDH2 encode highly homologous enzymes that are involved in the citric acid (TCA) cycle and other metabolic processes, playing roles in normal cellular metabolism and in protection against oxidative stress and apoptosis⁸⁰. R132 is located within the active site of IDH1 and is a hotspot for mutations in cancer⁸⁰⁻⁸⁴. Substitutions at IDH1 R132 alter the enzymatic activity of IDH1, resulting in the production of the oncometabolite, D-2-hydroxyglutarate (2-HG)⁸²⁻⁸⁶, which promotes tumorigenesis^{82,87-90}.

POTENTIAL DIAGNOSTIC IMPLICATIONS

IDH mutation in the absence of TERT mutation is suggestive of astrocytoma (NCCN CNS Cancers Guidelines, v2.2022)⁹¹. IDH1/2 mutation is associated with Grade 2 and 3 astrocytomas and oligodendrogliomas, with the latter also harboring 1p19q deletion, and distinguishes secondary glioblastoma (GBM) from primary GBM (NCCN CNS Cancers Guidelines, v2.2022). ATRX mutations often co-occur with IDH1/2 mutations and may be indicative of Grade 2-3 astrocytoma or secondary glioblastoma (GBM) (NCCN CNS Cancers Guidelines, v2.2022)⁹¹⁻⁹².

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 08 May 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1620418-01

GENOMIC FINDINGS

GENE

ATRX

ALTERATION

splice site 4557+1G>T

HGVS VARIANT

NM_000489.3: c.4557+1G>T (p.?)

VARIANT CHROMOSOMAL POSITION

chrX:76907603

VARIANT ALLELE FREQUENCY (% VAF)

81.6%

strand break-induction with agents such as doxorubicin, irinotecan, and topotecan⁹⁷; however, these approaches have not been demonstrated clinically.

FREQUENCY & PROGNOSIS

Somatic mutation of ATRX has been reported in a number of solid tumor types, often associated with ALT⁹⁸. ATRX mutation correlating with ALT has been reported in 10-20% of pancreatic neuroendocrine tumors (PNETs)⁹⁸⁻¹⁰⁰, 12.6% of pheochromocytomas and paragangliomas¹⁰¹, and 48% of adolescent and young adult (AYA) patients with glioblastoma (GBM) or neuroblastoma¹⁰²⁻¹⁰⁶. ATRX loss in PNET^{99,107} and melanoma¹⁰⁸ and mutation in other neuroendocrine tumors¹⁰¹ is associated with poor prognosis. Pediatric patients with high-grade glioma and ATRX mutation were shown to have more aggressive disease but are more responsive to treatment with double-strand break therapy⁹⁷. ATRX mutation or loss of expression is more frequent in Grade 2/3 astrocytoma and secondary GBM than primary GBM, oligodendroglioma, and oligoastrocytoma^{71,109-111} and has been proposed as a distinguishing biomarker^{71,110-111}. ATRX mutation has not been detected in concurrence with MYCN amplification in glioma and neuroblastoma¹⁰³⁻¹⁰⁶. Low-grade gliomas with both IDH1/2 mutation and ATRX mutation are associated with worse prognosis than those with IDH1/2 mutation but no

ATRX mutation⁷¹. Loss of ATRX protein expression has been reported in 33-39% of incidences of leiomyosarcoma (LMS) associating with ALT, a poor prognostic factor across all LMS subtypes, and with poor prognosis in extrauterine LMS but not in uterine LMS¹¹²⁻¹¹³.

FINDING SUMMARY

ATRX encodes a SWI/SNF chromatin remodeling protein implicated in histone variant H3.3 deposition, transcriptional regulation, and telomere maintenance¹¹⁴⁻¹¹⁵. ATRX inactivation or loss of expression is associated with alternative lengthening of telomeres (ALT)^{98,113,116-117}. Alterations that disrupt the ADD domain (aa 167-270) or helicase domain (aa 2010-2280) of ATRX are predicted to result in loss of ATRX function¹¹⁸⁻¹²⁰; however, the loss of ATRX function is not sufficient to induce ALT, which requires other undetermined factors^{114,121}. Germline mutations in ATRX give rise to alpha-thalassemia X-linked intellectual disability syndrome (ATR-X syndrome)¹²².

POTENTIAL DIAGNOSTIC IMPLICATIONS

ATRX mutations often co-occur with IDH1/2 mutations and may be indicative of Grade 2-3 astrocytoma or secondary glioblastoma (GBM) (NCCN CNS Cancers Guidelines, v2.2022)⁹¹⁻⁹².

GENE

FUBP1

ALTERATION

rearrangement intron 18

FREQUENCY & PROGNOSIS

FUBP1 alteration has been reported in 1.5% of samples analyzed in COSMIC, with the highest incidences reported in tumors of the endometrium (3.6%), central nervous system (3.2%), large intestine (3.0%), skin (2.8%), stomach (2.7%), and liver (2.6%) (COSMIC, Feb 2023)¹²³. One study reported higher expression of FUBP1 in colorectal carcinoma tissues compared to adenoma and normal colon epithelial tissues¹²⁴. A genetic signature defined by concomitant alterations in IDH1, CIC, and FUBP1 is associated with longer survival in patients with glioma¹²⁵. FUBP1 has been shown to activate the expression of MYC¹²⁶⁻¹²⁹, activate p27KIP1¹³⁰, and regulate the

splicing of MDM2¹³¹.

FINDING SUMMARY

FUBP1 encodes far upstream element binding protein 1 (also called FBP-1), a DNA-binding protein reported to have roles in transcriptional activation and splicing regulation of target genes. It is believed to act as an oncogene in some tumor types, such as hepatocellular carcinoma and non-small-cell lung cancer¹³²⁻¹³³, and as a tumor suppressor in others, particularly oligodendroglioma, for which mutations and/or loss of FUBP1 often co-occur with alterations in CIC or IDH1^{125,134-137}.

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Therapies targeting FUBP1 mutation directly or downstream effectors have not been tested preclinically or clinically in tumors that harbor FUBP1 mutations.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 08 May 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1620418-01

GENOMIC FINDINGS

GENE

TP53

ALTERATION

R282W

HGVS VARIANT

NM_000546.4: c.844C>T (p.R282W)

VARIANT CHROMOSOMAL POSITION

chr17:7577094

VARIANT ALLELE FREQUENCY (% VAF)

85.2%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib¹³⁸⁻¹⁴¹ or p53 gene therapy such as SGT53¹⁴²⁻¹⁴⁶. In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype¹⁴⁷. A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum-refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer¹⁴⁸. A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum-refractory TP53-mutated ovarian cancer¹⁴⁹. The combination of adavosertib with paclitaxel and carboplatin for patients with TP53-mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone¹⁵⁰. In the Phase 2 VIKTORY trial, patients with TP53-mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel¹⁵¹. A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck

squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations¹⁵². The Phase 2 FOCUS4-C trial for patients with TP53- and RAS-mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring¹⁵³. In a Phase 1b clinical trial of SGT-53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage¹⁴⁶. Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53-positive high-grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR¹⁵⁴. A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29)¹⁵⁵.

FREQUENCY & PROGNOSIS

TP53 mutations have been reported in 18-40% of astrocytoma samples, and preferentially in anaplastic astrocytoma; one study reported TP53 loss of function and partially/fully functional mutations in 15% and 25% of anaplastic astrocytomas, respectively¹⁵⁶⁻¹⁶¹. Some studies suggest that the presence of a TP53 mutation is correlated with a favorable prognosis in patients with glioblastoma (GBM)¹⁶². One study reported that TP53 alterations were associated with poorer OS (12.9 months altered vs. 19.7 months wildtype, HR=1.58, p=0.0054) in IDH-wildtype GBM¹⁶³. Mutation of TP53 is thought to be an early step in the tumorigenesis of astrocytomas, which can progress into anaplastic astrocytoma and then glioblastoma through gain of other genetic abnormalities such as loss of CDKN2A or RB1, followed by loss of PTEN¹⁶⁴.

FINDING SUMMARY

Functional loss of the tumor suppressor p53, which

is encoded by the TP53 gene, is common in aggressive advanced cancers¹⁶⁵. Alterations such as seen here may disrupt TP53 function or expression¹⁶⁶⁻¹⁷⁰.

POTENTIAL GERMLINE IMPLICATIONS

One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li-Fraumeni syndrome (ClinVar, Sep 2022)¹⁷¹. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers¹⁷²⁻¹⁷⁴, including sarcomas¹⁷⁵⁻¹⁷⁶. Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000¹⁷⁷ to 1:20,000¹⁷⁶. For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30¹⁷⁸. In the appropriate clinical context, germline testing of TP53 is recommended.

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion¹⁷⁹⁻¹⁸⁴. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy¹⁷⁹⁻¹⁸⁰. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease¹⁸⁵. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH^{183,186-187}. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 08 May 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1620418-01

THERAPIES WITH CLINICAL BENEFIT

IN OTHER TUMOR TYPE

Ivosidenib

Assay findings association
IDH1
R132H

AREAS OF THERAPEUTIC USE

Ivosidenib is an isocitrate dehydrogenase 1 (IDH1) inhibitor that is FDA approved to treat patients with a susceptible IDH1 mutation in relapsed or refractory acute myeloid leukemia (AML) or previously treated locally advanced or metastatic cholangiocarcinoma. It is also approved as a first-line treatment for patients with AML and a susceptible IDH1 mutation who are not eligible for intensive induction chemotherapy or who are ≥75 years old. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of extensive clinical evidence in AML¹⁸⁸ and

cholangiocarcinoma¹⁸⁹⁻¹⁹⁰ and limited clinical data in myelodysplastic syndrome (MDS)¹⁸⁸ and glioma^{50,191}, IDH1 R132 mutation may confer sensitivity to ivosidenib.

SUPPORTING DATA

In a Phase 1 study of ivosidenib for patients with IDH1-mutated advanced solid tumors, 1 patient achieved PR in the non-enhancing glioma population (ORR=2.9% [1/35]); for patients with non-enhancing glioma and enhancing glioma, SD rates were 85.7% (30/35) and 45.2% (14/31), respectively, and median PFS was 13.6 months and 1.4 months, respectively^{50,191}.

Olutasidenib

Assay findings association
IDH1
R132H

AREAS OF THERAPEUTIC USE

Olutasidenib is an isocitrate dehydrogenase 1 (IDH1) inhibitor that is FDA approved to treat patients with a susceptible IDH1 mutation in relapsed or refractory acute myeloid leukemia (AML). Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of extensive clinical data in acute myeloid leukemia (AML)¹⁹² and limited clinical data in both

myelodysplastic syndrome (MDS)¹⁹³ and glioma⁵¹, IDH1 R132 mutation may confer sensitivity to olutasidenib.

SUPPORTING DATA

The Phase 1b/2 trial investigating olutasidenib for patients with IDH1-mutated glioma reported a DCR of 48% (12/25, 2 PRs) and a median duration of disease control of 8.6 months; both PRs were observed for patients with enhancing high-grade glioma⁵¹.

NOTE Genomic alterations detected may be associated with activity of certain FDA approved drugs, however, the agents listed in this report may have varied evidence in the patient's tumor type.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 08 May 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1620418-01

CLINICAL TRIALS

NOTE Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually

updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials listed here may have additional enrollment criteria that

may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see [clinicaltrials.gov](https://www.clinicaltrials.gov). Or, visit <https://www.foundationmedicine.com/genomic-testing#support-services>.

GENE
IDH1
ALTERATION
R132H

RATIONALE
IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP

inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.

NCT02264678
PHASE 1/2

Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents

TARGETS
ATR, PARP, PD-L1

LOCATIONS: Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Goyang-si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)

NCT05417594
PHASE 1/2

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

TARGETS
PARP

LOCATIONS: Seoul (Korea, Republic of), Melbourne (Australia), Stockholm (Sweden), Barcelona (Spain), Sant Cugat del Valles (Spain), Pozuelo de Alarcon (Spain), A Coruña (Spain), Sevilla (Spain), Texas

NCT04740190
PHASE 2

Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

TARGETS
PARP

LOCATIONS: Hong Kong (Hong Kong)

NCT05035745
PHASE 1/2

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

TARGETS
XPO1, PARP

LOCATIONS: Singapore (Singapore)

NCT03772561
PHASE 1

Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies

TARGETS
PARP, AKTs, PD-L1

LOCATIONS: Singapore (Singapore)

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 08 May 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1620418-01

CLINICAL TRIALS
NCT05076513
PHASE NULL

Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma

TARGETS
PARP

LOCATIONS: Arizona

NCT04801966
PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

NCT04991480
PHASE 1/2

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

TARGETS
PARP, Pol theta

LOCATIONS: London (United Kingdom), Oklahoma, Connecticut, New York, Pennsylvania, Tennessee, Texas, Florida

NCT03212274
PHASE 2

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

TARGETS
PARP

LOCATIONS: California, Wisconsin, Missouri, Kansas

NCT05327010
PHASE 2

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

TARGETS
PARP, BRD4, BRDT, BRD2, BRD3

LOCATIONS: Illinois, Texas, North Carolina, Georgia

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 08 May 2023
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1620418-01

APPENDIX
Variants of Unknown Significance

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

EPHB4

 NM_004444.4: c.2033G>A
(p.R678H)
chr7:100410454

MITF

 NM_198159.2: c.38T>C
(p.V13A)
chr3:69788786

NOTCH3

 NM_000435.2: c.3523C>T
(p.R1175W)
chr19:15290031

PARP3

 NM_005485.4: c.1223G>A
(p.R408H)
chr3:51980306

PIK3C2G

 NM_004570.4:
c.3299_3306dup
(p.Y1103Vfs*15)
chr12:18691183

POLD1

 NM_002691.2: c.371T>C
(p.V124A)
chr19:50905089

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

 Electronically signed by Erik Williams, M.D. | 08 May 2023
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | www.rochefoundationmedicine.com

 Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1620418-01

APPENDIX
Genes Assayed in FoundationOne®CDx

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	ACVR1B	AKT1	AKT2	AKT3	ALK	ALOX12B	AMER1 (FAM123B or WTX)	
APC	AR	ARAF	ARFRP1	ARID1A	ASXL1	ATM	ATR	ATRX
AURKA	AURKB	AXIN1	AXL	BAP1	BARD1	BCL2	BCL2L1	BCL2L2
BCL6	BCOR	BCORL1	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1
BTG2	BTK	CALR	CARD11	CASP8	CBFB	CBL	CCND1	CCND2
CCND3	CCNE1	CD22	CD274 (PD-L1)	CD70	CD79A	CD79B	CDC73	CDH1
CDK12	CDK4	CDK6	CDK8	CDKN1A	CDKN1B	CDKN2A	CDKN2B	CDKN2C
CEBPA	CHEK1	CHEK2	CIC	CREBBP	CRKL	CSF1R	CSF3R	CTCF
CTNNA1	CTNNB1	CUL3	CUL4A	CXCR4	CYP17A1	DAXX	DDR1	DDR2
DIS3	DNMT3A	DOT1L	EED	EGFR	EMSY (C11orf30)	EP300	EPHA3	EPHB1
EPHB4	ERBB2	ERBB3	ERBB4	ERCC4	ERG	ERRF1	ESR1	EZH2
FANCA	FANCC	FANCG	FANCL	FAS	FBXW7	FGF10	FGF12	FGF14
FGF19	FGF23	FGF3	FGF4	FGF6	FGFR1	FGFR2	FGFR3	FGFR4
FH	FLCN	FLT1	FLT3	FOXL2	FUBP1	GABRA6	GATA3	GATA4
GATA6	GID4 (C17orf39)	GNA11	GNA13	GNAS	GNAS	GRM3	GSK3B	H3-3A (H3F3A)
HDAC1	HGF	HNFI1A	HRAS	HSD3B1	ID3	IDH1	IDH2	IGF1R
IKBKE	IKZF1	INPP4B	IRF2	IRF4	IRS2	JAK1	JAK2	JAK3
JUN	KDM5A	KDM5C	KDM6A	KDR	KEAP1	KEL	KIT	KLHL6
KMT2A (MLL)	KMT2D (MLL2)	KRAS	LTK	LYN	MAF	MAP2K1 (MEK1)	MAP2K2 (MEK2)	MAP2K4
MAP3K1	MAP3K13	MAPK1	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1
MERTK	MET	MITF	MKNK1	MLH1	MPL	MRE11 (MRE11A)	MSH2	MSH3
MSH6	MST1R	MTAP	MTOR	MUTYH	MYC	MYCL (MYCL1)	MYCN	MYD88
NBN	NF1	NF2	NFE2L2	NFKBIA	NKX2-1	NOTCH1	NOTCH2	NOTCH3
NPM1	NRAS	NSD2 (WHSC1 or MMSET)	NSD3 (WHSC1L1)	NT5C2	NTRK1	NTRK2	NTRK3	NTRK3
P2RY8	PALB2	PARP1	PARP2	PARP3	PAX5	PBRM1	PDCD1 (PD-1)	PDCD1LG2 (PD-L2)
PDGFRA	PDGFRB	PDK1	PIK3C2B	PIK3C2G	PIK3CA	PIK3CB	PIK3R1	PIM1
PMS2	POLD1	POLE	PPARG	PPP2R1A	PPP2R2A	PRDM1	PRKAR1A	PRKCI
PRKN (PARK2)	PTCH1	PTEN	PTPN11	PTPRO	QKI	RAC1	RAD21	RAD51
RAD51B	RAD51C	RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10
REL	RET	RICTOR	RNF43	ROS1	RPTOR	SDHA	SDHB	SDHC
SDHD	SETD2	SF3B1	SGK1	SMAD2	SMAD4	SMARCA4	SMARCB1	SMO
SNCAIP	SOC1	SOX2	SOX9	SPEN	SPOP	SRC	STAG2	STAT3
STK11	SUFU	SYK	TBX3	TEK	TENT5C (FAM46C)	TET2	TET2	TGFB2
TIPARP	TNFAIP3	TNFRSF14	TP53	TSC1	TSC2	TYRO3	U2AF1	VEGFA
VHL	WT1	XPO1	XRCC2	ZNF217	ZNF703			

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	BCL2	BCR	BRAF	BRCA1	BRCA2	CD74	EGFR	ETV4
ETV5	ETV6	EWSR1	EZR	FGFR1	FGFR2	FGFR3	KIT	KMT2A (MLL)
MSH2	MYB	MYC	NOTCH2	NTRK1	NTRK2	NUTM1	PDGFRA	RAF1
RARA	RET	ROS1	RSP02	SDC4	SLC34A2	TERC*	TERT**	TPRSS2

*TERC is an NCRNA

**Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS


Homologous Recombination status
Loss of Heterozygosity (LOH) score
Microsatellite (MS) status
Tumor Mutational Burden (TMB)

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

ORDERED TEST # ORD-1620418-01

APPENDIX

About FoundationOne®CDx

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Ciplstraat 3, 2440 Geel, Belgium. 

ABOUT FOUNDATIONONE CDx

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details:
www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLE

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes

detection of alterations in a total of 324 genes.

Using an Illumina® HiSeq platform, hybrid capture-selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g. gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for *ERBB2* and six (6) for all other genes. Conversely, an alteration denoted as "loss – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical

methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Therapies and Clinical Trials

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Limitations

1. In the fraction-based MSI algorithm, a tumor specimen will be categorized as MSI-H, MSS, or MS-Equivocal according to the fraction of microsatellite loci determined to be altered or unstable (i.e., the fraction unstable loci score). In the F1CDx assay, MSI is evaluated based on a genome-wide analysis across >2000 microsatellite loci. For a given microsatellite locus, non-somatic alleles are discarded, and the microsatellite is categorized as unstable if remaining alleles differ from the reference genome. The final fraction unstable loci score is calculated as the number of unstable microsatellite loci divided by the number of evaluable microsatellite loci. The MSI-H and MSS cut-off thresholds were determined by

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 08 May 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1620418-01

APPENDIX

About FoundationOne®CDx

- analytical concordance to a PCR comparator assay using a pan-tumor FFPE tissue sample set. Patients with results categorized as "MS-Stable" with median exon coverage <300X, "MS-Equivocal," or "Cannot Be Determined" should receive confirmatory testing using a validated orthogonal (alternative) method.
- TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.
 - Homologous Recombination status may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas (Coleman et al., 2017; 28916367). Samples with deleterious *BRCA1/2* alteration and/or Loss of Heterozygosity (LOH) score $\geq 16\%$ will be reported as "HRD Positive" and samples with absence of these findings will be reported as "HRD Not Detected," agnostic of potential secondary *BRCA1/2* reversion alterations. Certain potentially deleterious missense or small in-frame deletions in *BRCA1/2* may not be classified as deleterious and, in the absence of an elevated LOH profile, samples with such mutations may be classified as "HRD Not Detected." A result of "HRD Not Detected" does not rule out the presence of a *BRCA1/2* alteration or an elevated LOH profile outside the assay performance characteristic limitations.
 - The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and

extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.

- Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
- Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.
- Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in <https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/> report the frequency of HER2 overexpression as 20% in breast cancer. Based on the F1CDx HER2 CDx concordance study, approximately 10% of HER2 amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal

hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	%CV*
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

*Interquartile Range = 1st Quartile to 3rd Quartile

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM*, *BAP1*, *BRCA1*, *BRCA2*, *BRIP1*, *CHEK2*, *FH*, *FLCN*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *PALB2*, *PMS2*, *POLE*, *RAD51C*, *RAD51D*, *RET*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *TSC2*, and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 08 May 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1620418-01

APPENDIX

About FoundationOne®CDx

tumor sequencing is germline or somatic.
Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1*, *CBL*, *DNMT3A*, *IDH2*, *JAK2*, *KMT2D (MLL2)*, *MPL*, *MYD88*, *SF3B1*, *TET2*, and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking

into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
mut/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

REFERENCE SEQUENCE INFORMATION

Sequence data is mapped to the human genome, Genome Reference Consortium Human Build 37 (GRCh37), also known as hg19.

MR Suite Version (RG) 7.8.0

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of the data. Please refer to the original report for the suitability of use.

The median exon coverage for this sample is 752x

ORDERED TEST # ORD-1620418-01

APPENDIX
References

1. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) PMID: 25392179
2. Kroemer G, et al. Oncoimmunology (2015) PMID: 26140250
3. Lal N, et al. Oncoimmunology (2015) PMID: 25949894
4. Le DT, et al. N. Engl. J. Med. (2015) PMID: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Alonso M, et al. Cancer Res. (2001) PMID: 11280776
7. Rodríguez-Hernández I, et al. PLoS ONE (2013) PMID: 24073290
8. Vladimirova V, et al. Neuropathol. Appl. Neurobiol. (2008) PMID: 18053027
9. Martinez R, et al. Oncology (2004) PMID: 15331927
10. Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) PMID: 15672285
11. Martinez R, et al. Cancer Genet. Cytogenet. (2007) PMID: 17498554
12. Szybka M, et al. Clin. Neuropathol. (2015) PMID: 12908754
13. Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) PMID: 26337942
14. You JF, et al. Br. J. Cancer (2010) PMID: 21081928
15. Bairwa NK, et al. Methods Mol. Biol. (2014) PMID: 24623249
16. Boland CR, et al. Cancer Res. (1998) PMID: 9823339
17. Pawlik TM, et al. Dis. Markers (2004) PMID: 15528785
18. Boland CR, et al. Gastroenterology (2010) PMID: 20420947
19. Samstein RM, et al. Nat. Genet. (2019) PMID: 30643254
20. Goodman AM, et al. Mol. Cancer Ther. (2017) PMID: 28835386
21. Goodman AM, et al. Cancer Immunol Res (2019) PMID: 31405947
22. Cristescu R, et al. Science (2018) PMID: 30309915
23. Ready N, et al. J. Clin. Oncol. (2019) PMID: 30785829
24. Hellmann MD, et al. N. Engl. J. Med. (2018) PMID: 29658845
25. Hellmann MD, et al. Cancer Cell (2018) PMID: 29657128
26. Hellmann MD, et al. Cancer Cell (2018) PMID: 29731394
27. Rozeman EA, et al. Nat Med (2021) PMID: 33558721
28. Sharma P, et al. Cancer Cell (2020) PMID: 32916128
29. Zhao J, et al. Nat. Med. (2019) PMID: 30742119
30. Touat M, et al. Nature (2020) PMID: 32322066
31. Bouffet E, et al. J. Clin. Oncol. (2016) PMID: 27001570
32. Johanns TM, et al. Cancer Discov (2016) PMID: 27683556
33. Lukas RV, et al. J. Neurooncol. (2018) PMID: 30073642
34. Chalmers ZR, et al. Genome Med (2017) PMID: 28420421
35. Patel RR, et al. Pediatr Blood Cancer (2020) PMID: 32386112
36. Johnson A, et al. Oncologist (2017) PMID: 28912153
37. Draaisma K, et al. Acta Neuropathol Commun (2015) PMID: 26699864
38. Wang L, et al. BMC Cancer (2020) PMID: 32164609
39. Pfeifer GP, et al. Mutat. Res. (2005) PMID: 15748635
40. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) PMID: 23875803
41. Pfeifer GP, et al. Oncogene (2002) PMID: 12379884
42. Rizvi NA, et al. Science (2015) PMID: 25765070
43. Johnson BE, et al. Science (2014) PMID: 24336570
44. Choi S, et al. Neuro-oncology (2018) PMID: 29452419
45. Cancer Genome Atlas Research Network, et al. Nature (2013) PMID: 23636398
46. Briggs S, et al. J. Pathol. (2013) PMID: 23447401
47. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) PMID: 24583393
48. Nature (2012) PMID: 22810696
49. Roberts SA, et al. Nat. Rev. Cancer (2014) PMID: 25568919
50. Fan B, et al. Invest New Drugs (2019) PMID: 31028664
51. de la Fuente MI, et al. Neuro Oncol (2022) PMID: 35639513
52. Mellinshoff et al., 2020; ASCO Abstract 2504
53. Philip B, et al. Cell Rep (2018) PMID: 29719265
54. Molenaar RJ, et al. Clin. Cancer Res. (2018) PMID: 29339439
55. Lu Y, et al. Cancer Res. (2017) PMID: 28202508
56. Sulkowski PL, et al. Sci Transl Med (2017) PMID: 28148839
57. Natsume A, et al. Neuro Oncol (2022) PMID: 35722822
58. McBrayer SK, et al. Cell (2018) PMID: 30220459
59. Cairncross JG, et al. J Clin Oncol (2014) PMID: 24516018
60. van den Bent MJ, et al. Lancet Oncol (2021) PMID: 34000245
61. Esteyrie V, et al. Oncologist (2021) PMID: 33524191
62. Chaumeil MM, et al. Nat Commun (2013) PMID: 24019001
63. Hartmann C, et al. Clin. Cancer Res. (2013) PMID: 23918605
64. Rossetto M, et al. Rev. Neurol. (Paris) (2011) PMID: 21885076
65. Shin JH, et al. J. Neurooncol. (2013) PMID: 24129546
66. Parsons DW, et al. Science (2008) PMID: 18772396
67. Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) PMID: 26061751
68. Brennan CW, et al. Cell (2013) PMID: 24120142
69. Thota B, et al. Am. J. Clin. Pathol. (2012) PMID: 22904127
70. Killela PJ, et al. Oncotarget (2014) PMID: 24140581
71. Haberler C, et al. Clin. Neuropathol. (2015) PMID: 24559763
72. Yan H, et al. N. Engl. J. Med. (2009) PMID: 19228619
73. Hartmann C, et al. Acta Neuropathol. (2010) PMID: 21088844
74. Sonoda Y, et al. Cancer Sci. (2009) PMID: 19765000
75. Ahmadi R, et al. J. Neurooncol. (2012) PMID: 22528790
76. Jiang H, et al. Neuro-oncology (2013) PMID: 23486687
77. Shibahara I, et al. Int. J. Clin. Oncol. (2012) PMID: 21971842
78. Juratli TA, et al. J. Neurooncol. (2012) PMID: 23015095
79. Weller M, et al. J. Clin. Oncol. (2009) PMID: 19805672
80. Johtman ZJ, et al. J. Natl. Cancer Inst. (2010) PMID: 20513808
81. Jin G, et al. PLoS ONE (2011) PMID: 21326614
82. Gross S, et al. J. Exp. Med. (2010) PMID: 20142433
83. Ward PS, et al. Cancer Cell (2010) PMID: 20171147
84. Leonardi R, et al. J. Biol. Chem. (2012) PMID: 22442146
85. Dang L, et al. Nature (2009) PMID: 19935646
86. Ward PS, et al. Oncogene (2012) PMID: 21996744
87. Figueroa ME, et al. Cancer Cell (2010) PMID: 21130701
88. Xu W, et al. Cancer Cell (2011) PMID: 21251613
89. Turcan S, et al. Nature (2012) PMID: 22343889
90. Duncan CG, et al. Genome Res. (2012) PMID: 22899282
91. Weller M, et al. Nat Rev Clin Oncol (2021) PMID: 33293629
92. Louis DN, et al. Acta Neuropathol (2016) PMID: 27157931
93. Liang J, et al. Cancer Res (2020) PMID: 31551363
94. Garbarino J, et al. Transl Oncol (2021) PMID: 34118569
95. Cole et al., 2021; AACR Abstract CT059
96. George SL, et al. EBioMedicine (2020) PMID: 32846370
97. Koschmann C, et al. Sci Transl Med (2016) PMID: 26936505
98. Heaphy CM, et al. Science (2011) PMID: 21719641
99. Singhi et al., 2015; USCAP Abstract 1797
100. Jiao Y, et al. Science (2011) PMID: 21252315
101. Fishbein L, et al. Nat Commun (2015) PMID: 25608029
102. Morosini et al., 2014; ASCO Abstract 11008
103. Cheung NK, et al. JAMA (2012) PMID: 22416102
104. Molenaar JJ, et al. Nature (2012) PMID: 22367537
105. Pugh TJ, et al. Nat. Genet. (2013) PMID: 23334666
106. Cheung NK, et al. Nat. Rev. Cancer (2013) PMID: 23702928
107. Marinoni I, et al. Gastroenterology (2014) PMID: 24148618
108. Qadeer ZA, et al. J. Invest. Dermatol. (2014) PMID: 24468746
109. Kannan K, et al. Oncotarget (2012) PMID: 23104868
110. Reuss DE, et al. Acta Neuropathol. (2015) PMID: 25427834
111. Sahm F, et al. Acta Neuropathol. (2014) PMID: 25143301
112. Singhi et al., 2015; USCAP Abstract 93
113. Liao JY, et al. Am. J. Surg. Pathol. (2015) PMID: 25229770
114. Clynes D, et al. Trends Biochem. Sci. (2013) PMID: 23916100
115. Ratnakumar K, et al. Epigenetics (2013) PMID: 23249563
116. Lovejoy CA, et al. PLoS Genet. (2012) PMID: 22829774
117. Bower K, et al. PLoS ONE (2012) PMID: 23185534
118. Nan X, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) PMID: 17296936
119. Garrick D, et al. Gene (2004) PMID: 14729260
120. Eustermann S, et al. Nat. Struct. Mol. Biol. (2011) PMID: 21666677
121. Flynn RL, et al. Science (2015) PMID: 25593184
122. Gibbons RJ, et al. Cell (1995) PMID: 7697714
123. Tate JG, et al. Nucleic Acids Res. (2019) PMID: 30371878
124. Jia MY, et al. Neoplasia (2014) PMID: 25030436
125. Jiao Y, et al. Oncotarget (2012) PMID: 22869205
126. Duncan R, et al. Genes Dev. (1994) PMID: 8125259
127. Kim MJ, et al. Nat. Genet. (2003) PMID: 12819782
128. Weber A, et al. BMC Cancer (2008) PMID: 19087307
129. Jang M, et al. Oncogene (2009) PMID: 19219071
130. Zheng Y, et al. Int. J. Biochem. Cell Biol. (2011) PMID: 21855647
131. Jacob AG, et al. J. Biol. Chem. (2014) PMID: 24798327
132. Rabenhorst U, et al. Hepatology (2009) PMID: 19637194
133. Singer S, et al. Cancer Res. (2009) PMID: 19258502
134. Sahm F, et al. Acta Neuropathol. (2012) PMID: 22588899
135. Bettgowda C, et al. Science (2011) PMID: 21817013
136. Baumgarten P, et al. Neuropathol. Appl. Neurobiol. (2014) PMID: 24117486
137. Chan AK, et al. Mod. Pathol. (2014) PMID: 24030748
138. Hirai H, et al. Cancer Biol. Ther. (2010) PMID: 20107315
139. Bridges KA, et al. Clin. Cancer Res. (2011) PMID: 21799033
140. Rajeshkumar NV, et al. Clin. Cancer Res. (2011) PMID: 21389100
141. Osman AA, et al. Mol. Cancer Ther. (2015) PMID: 25504633
142. Xu L, et al. Mol. Cancer Ther. (2002) PMID: 12489850
143. Xu L, et al. Mol. Med. (2001) PMID: 11713371
144. Camp ER, et al. Cancer Gene Ther. (2013) PMID: 23470564
145. Kim SS, et al. Nanomedicine (2015) PMID: 25240597
146. Pirolo KF, et al. Mol. Ther. (2016) PMID: 27357628
147. Leijen S, et al. J. Clin. Oncol. (2016) PMID: 27601554
148. Moore et al., 2019; ASCO Abstract 5513

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

ORDERED TEST # ORD-1620418-01

APPENDIX
References

149. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224
150. Oza et al., 2015; ASCO Abstract 5506
151. Lee J, et al. Cancer Discov (2019) pmid: 31315834
152. Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125
153. Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072
154. Gourley et al., 2016; ASCO Abstract 5571
155. Park H, et al. ESMO Open (2022) pmid: 36084396
156. Uno M, et al. Cancer Lett. (2005) pmid: 15914282
157. Uno M, et al. Int. J. Biol. Markers () pmid: 16711514
158. Lass U, et al. PLoS ONE (2012) pmid: 22844452
159. Faria MH, et al. APMIS (2012) pmid: 23009112
160. Milinkovic V, et al. PLoS ONE (2013) pmid: 24358143
161. Galatro TF, et al. PLoS ONE (2013) pmid: 23613880
162. Schmidt MC, et al. J. Neuropathol. Exp. Neurol. (2002) pmid: 11939587
163. Yan et al. 2020; DOI:10.1200/PO.19.00385
164. Nozaki M, et al. Neuro-oncology (1999) pmid: 11550308
165. Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675
166. Joergers AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249
167. Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609
168. Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130
169. Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496
170. Yamada H, et al. Carcinogenesis (2007) pmid: 17690113
171. Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669
172. Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290
173. Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100
174. Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776
175. Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316
176. Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208
177. Laloo F, et al. Lancet (2003) pmid: 12672316
178. Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713
179. Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837
180. Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838
181. Xie M, et al. Nat. Med. (2014) pmid: 25326804
182. Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404
183. Severson EA, et al. Blood (2018) pmid: 29678827
184. Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212
185. Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320
186. Chabon JJ, et al. Nature (2020) pmid: 32269342
187. Razavi P, et al. Nat. Med. (2019) pmid: 31768066
188. DiNardo CD, et al. N. Engl. J. Med. (2018) pmid: 29860938
189. Lowery MA, et al. Lancet Gastroenterol Hepatol (2019) pmid: 31300360
190. Abou-Alfa GK, et al. Lancet Oncol. (2020) pmid: 32416072
191. Mellingerhoff IK, et al. J. Clin. Oncol. (2020) pmid: 32530764
192. Cortes et al., 2022; ASH Abstract 2757
193. Watts JM, et al. Lancet Haematol (2022) pmid: 36370742

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 08 May 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531